Recent Updates
Recently added Catalysts

Pirfenidone

Phase 2

Idiopathic Pulmonary Fibrosis | Small molecule | Respiratory |PureTech Health plc|Last Updated: Oct 15, 2025

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment240
FDA Designations
No designations recorded
Clinical trial landscape

Pirfenidone · 1 trial · 1 indication

Phase 2 1
NCT05321420LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis
ACTIVE NOT_RECRUITING240 Analytics
PHASE2ACTIVE NOT_RECRUITING
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
NCT05321420240
Unlock trial analytics
Study Design & Arms
Interventions
NameTypeDescription
PlaceboDRUGplacebo
PirfenidoneDRUGpirfenidone 801 mg TID
DeupirfenidoneDRUGDeupirfenidone
Unlock Study Design Details
Competitive Landscape -Idiopathic Pulmonary Fibrosis 20 trials
CompanyTickerTrialsLead PhaseDrugs
Bristol-Myers Squibb CompanyBMY2PHASE3BMS-986278
United Therapeutics CorporationUTHR2PHASE3Treprostinil
PureTech Health PLC Sponsored ADRPRTC2PHASE3Deupirfenidone, Pirfenidone
AbbVie, Inc.ABBV2PHASE2ABBV-142
Syndax Pharmaceuticals IncSNDX1PHASE2Axatilimab
Contineum Therapeutics, Inc. Class ACTNM1PHASE2PIPE-791 Dose A, PIPE-791 Dose B
Rein Therapeutics, IncRNTX1PHASE2LTI-03
Sunshine Biopharma IncorporatedSBFM2PHASE3HEC585, Pirfenidone
Cumberland Pharmaceuticals Inc.CPIX1PHASE2Ifetroban
Avalyn Pharma IncAVLN3PHASE2AP01
Trevi Therapeutics, Inc.TRVI1PHASE1NAL
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT05321420studyFirstPostDate: changed